Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Purpose
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Conditions
- Brain Tumor, Recurrent
- Brain Tumor
- Brain Tumor, Primary
- Brain Tumor - Metastatic
- Brain Tumor, Adult: Glioblastoma
- Brain Tumor, Adult Meningioma
Eligibility
- Eligible Ages
- All ages
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles. 2. Willing and able to provide informed consent and to participate in all evaluations.
Exclusion Criteria
- Inability to undergo pre-operative and post-operative imaging for disease and implant assessment. 2. Major medical or psychiatric illness, which, in the investigator's opinion would prevent completion of treatment, ability to complete assessments at the time of enrollment, and/or interfere with follow ups. 3. Lack of English language fluency sufficient to allow for completion of neurocognitive and QOL tests (which are in English).
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
GammaTile | Patients who have received permanent implants of GammaTile radiation therapy immediately following brain tumor resection. |
|
Recruiting Locations
Phoenix, Arizona 85027
John Wanebo, MD
Little Rock, Arkansas 72205
Analiz Rodriguez, MD, PhD
501-296-1138
Castro Valley, California 94546
Lawrence Dickinson, MD
925-884-2360
La Jolla, California 92093
David Piccioni, MD, PhD
Palm Springs, California 92262
Amir Lavaf, MD
760-416-4770
San Francisco, California 94109
Lewis Leng, MD
415-600-0528
Englewood, Colorado 80113
Vadim Tsvankin, MD
303-783-8844
Clearwater, Florida 33756
Devon Haydon, MD
Miami, Florida 33176
Rupesh Kotecha, MD
Orlando, Florida 32803
Imran Mohiuddin, MD
407-303-2030
Orlando, Florida 32806
Catherine Mercado, MD
Tampa, Florida 33606
Tulika Ranjan, MD
Weston, Florida 33331
Surabhi Ranjan, MD, FACP
954-659-5670
Atlanta, Georgia 30309
Adam Nowlan, MD
Atlanta, Georgia 30322
Kimberly Bojanowski
Boise, Idaho 83704
Ondrej Choutka
Indianapolis, Indiana 46202
Mitesh Shah
Kansas City, Kansas 66160
Kushal Shah
Louisville, Kentucky 40202
Akshitkumar Mistry, MD
502-588-2160
Louisville, Kentucky 40241
Detroit, Michigan 48202
Adam M Robin, MD
Minneapolis, Minnesota 55407
John Trusheim, MD
Minneapolis, Minnesota 55414
Clark Chen, MD
Omaha, Nebraska 68198
Michele Aizenberg, MD
402-559-6704
Albany, New York 12208
Tuba Ahmed
518-262-5088
Syracuse, New York 13210
Harish Babu, MD
315-464-4470
Valhalla, New York 10595
Simon Hanft
Chapel Hill, North Carolina 27599
Colette Shen, MD
Greenville, North Carolina 27834
Stuart Lee, MD
252-847-1550
Wilmington, North Carolina 28401
Cincinnati, Ohio 45209
Vincent DiNapoli, MD
513-888-7564
Kettering, Ohio 45429
Mark Hoeprich, MD
937-298-4331
Allentown, Pennsylvania 18102
Chattanooga, Tennessee 37404
Dallas, Texas 75235
Toral Patel, MD
Houston, Texas 77030
Akash Patel, MD
713-798-8810
Houston, Texas 77030
David Baskin, MD
San Antonio, Texas 78229
John Floyd, MD
The Woodlands, Texas 77380
Seattle, Washington 98101
Huong Pham, MD
206-287-6278
More Details
- NCT ID
- NCT04427384
- Status
- Recruiting
- Sponsor
- GT Medical Technologies, Inc.
Detailed Description
Patients (N=600) with surgically resected (R) brain tumors of any pathology who have undergone STaRT are eligible. Data collected will include local control, overall survival, QOL, neurocognition, functional decline, and surgical and radiation associated AE's. Data will be collected at 1, 3, 6, 9,12, 18 and 24 months, then every 6 months through 5 years. RESULT: Data will be used to benchmark clinical outcomes of STaRT therapy and allow for comparisons to existing standard-of-care treatments. This will be the first observational registry study of R+STaRT, delivered by Cs-131 sources in permanently implanted resorbable collagen tile carriers. The outcome measures captured will allow for evaluation of the potential risks and benefits of this treatment approach for patients in a real-world setting.